A prodrug nanoparticle approach for the oral delivery of a hydrophilic peptide, leucine5-enkephalin, to the brain

Molecular Pharmaceutics

Volumn 9, Issue 6, 2012, Pages 1665-1680

  Lalatsa, Aikaterini ^a   Lee, Vivian ^a   Malkinson, John P ^a   Zloh, Mire ^a   Schätzlein, Andreas G ^a   Uchegbu, Ijeoma F ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

blood brain barrier; chitosan amphiphiles; GCPQ; leucine5 enkephalin; oral; peptides; quaternary ammonium palmitoyl glycol chitosan

Indexed keywords

AMPHOPHILE; CHITOSAN; LEUCINE ENKEPHALIN; NANOPARTICLE; NEUROPEPTIDE; PALMITIC ACID DERIVATIVE; PLASMA PROTEIN; PRODRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BRAIN LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; MALE; MOUSE; NANOENCAPSULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN STABILITY; RAT; URINARY EXCRETION;

ADMINISTRATION, ORAL; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; ENKEPHALINS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MASS SPECTROMETRY; MICE; NANOPARTICLES; PEPTIDES; PRODRUGS; RATS; RATS, WISTAR;

EID: 84862015361     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp300009u     Document Type: Article

References (64)

1. Shenderovich, M. D.; Liao, S. B.; Qian, X. H.; Hruby, V. J. A three-dimensional model of the delta-opioid pharmacophore: Comparative molecular modeling of peptide and nonpeptide ligands. Biopolymers 2000, 53 (7), 565-580. (Pubitemid 30230409)
2. Jablensky, A. Epidemiology of schizophrenia: the global burden of disease and disability. Eur. Arch. Psychiatr. Clin. Neurosci. 2000, 250(6), 274-285. (Pubitemid 32002381)
3. Mayeux, R. Epidemiology of neurodegeneration. Annu. Rev. Neurosci. 2003, 26, 81-104. (Pubitemid 37064929)
4. Khuntia, D.; Brown, P.; Li, J.; Mehta, M. P. Whole-brain radiotherapy in the management of brain metastasis. J. Clin. Oncol. 2006, 24 (8), 1295-1304. (Pubitemid 46622033)
5. World Health Organisation. World Mental Health Day 2006: Building Awareness - Reducing Risks: Suicide and Mental Illness. 2006, http://www.who.int/mediacentre/news/releases/2006/pr53/ en/.
6. Karls, M. S.; Rush, B. D.; Wilkinson, K. F.; Vidmar, T. J.; Burton, P. S.; Ruwart, M. J. Desolvation Energy - a Major Determinant of Absorption, but Not Clearance, of Peptides in Rats. Pharm. Res. 1991, 8 (12), 1477-1481.
7. Pauletti, G. M.; Gangwar, S.; Siahaan, T. J.; Aube, J.; Borchardt, R. T. Improvement of oral peptide bioavailability: Peptidomimetics and prodrug strategies. Adv. Drug Delivery Rev. 1997, 27 (2-3), 235-256. (Pubitemid 27417875)
8. Sokolov, O. Y.; Kurasova, O. B.; Kost, N. V.; Gabaeva, M. V.; Korneeva, E. V.; Mikheeva, I. G.; Zozulya, A. A. Half-life of leuenkephalin in the serum of infants of the first year of life on different types of feeding: relationship with temperament. Bull. Exp. Biol. Med. 2004, 137 (4), 342-344. (Pubitemid 38992444)
9. Elsayed, A.; Al Remawi, M.; Qinna, N. Farouk, A.; Badwan, A. Formulation and characterization of an oily-based system for oral delivery of insulin. Eur. J. Pharm. Biopharm. 2009, 73 (2), 269-279.
10. Paul, W.; Sharma, C. P. Tricalcium phosphate delayed release formulation for oral delivery of insulin: A proof-of-concept study. J. Pharm. Sci. 2008, 97 (2), 875-882. (Pubitemid 351293887)
11. Chalasani, K. B.; Russell-Jones, G. J.; Jain, A. K.; Diwan, P. V.; Jain, S. K. Effective oral delivery of insulin in animal models using vitamin B12-coated dextran nanoparticles. J. Controlled Release 2007, 122 (2), 141-150. (Pubitemid 47361403)
12. Martins, S.; Silva, A. C.; Ferreira, D. C.; Souto, E. B. Improving Oral Absorption of Samon Calcitonin by Trimyristin Lipid Nanoparticles. J. Biomed. Nanotechnol. 2009, 5 (1), 76-83.
13. Fasano, A.; Uzzau, S. Modulation of intestinal tight junctions by Zonula occludens toxin permits enteral administration of insulin and other macromolecules in an animal model. J. Clin. Invest. 1997, 99 (6), 1158-1164. (Pubitemid 27142750)
14. Wang, J.; Hogenkamp, D. J.; Tran, M.; Li, W. Y.; Yoshimura, R. F.; Johnstone, T. B. C.; Shen, W. C.; Gee, K. W. Reversible lipidization for the oral delivery of leu-enkephalin. J. Drug Targeting 2006, 14 (3), 127-136. (Pubitemid 43878821)
15. Deeken, J. F.; Loscher, W. The blood-brain barrier and cancer: Transporters, treatment, and Trojan horses. Clin. Cancer Res. 2007, 13 (6), 1663-1674. (Pubitemid 46952931)
16. Pardridge, W. M. The Blood-Brain Barrier: Bottleneck in Brain Drug Development. J. Am. Soc. Exp. NeuroTher. 2005, 2, 3-14. (Pubitemid 40128022)
17. Begley, D. J. The blood-brain barrier: Principles for targeting peptides and drugs to the central nervous system. J. Pharm. Pharmacol. 1996, 48 (2), 136-146. (Pubitemid 26129083)
18. Begley, D. J. ABC transporters and the blood-brain barrier. Curr. Pharm. Des. 2004, 10 (12), 1295-1312. (Pubitemid 38559749)
19. Lalatsa, A.; Schätzlein, A. G.; Uchegbu, I. F. Drug delivery across the blood brain barrier. In Comprehensive Biotechnology, 2nd ed.; Moo- Young, M.; Butler, M., Webb, C., Moreira, A., Grodzinski, B., Cui, Z., Eds.; Elsevier: Amsterdam, 2011; pp 657-668.
20. Batrakova, E. V.; Vinogradov, S. V.; Robinson, S. M.; Niehoff, M. L.; Banks, W. A.; Kabanov, A. V. Polypeptide point modifications with fatty acid and amphiphilic block copolymers for enhanced brain delivery. Bioconjugate Chem. 2005, 16 (4), 793-802. (Pubitemid 41026165)
21. Rousselle, C.; Clair, P.; Smirnova, M.; Kolesnikov, Y.; Pasternak, G. W.; Gac-Breton, S.; Rees, A. R.; Scherrmann, J. M.; Temsamani, J. Improved brain uptake and pharmacological activity of dalargin using a peptide-vector-mediated strategy. J. Pharmacol. Exp. Ther. 2003, 306 (1), 371-376. (Pubitemid 36734394)
22. Pardridge, W. M. Drug targeting to the brain. Pharm. Res. 2007, 24 (9), 1733-1744. (Pubitemid 47206623)
23. Beduneau, A.; Hindre, F.; Clavreul, A.; Leroux, J. C.; Saulnier, P.; Benoit, J. P. Brain targeting using novel lipid nanovectors. J. Controlled Release 2008, 126 (1), 44-49.
24. Pardridge, W. M.; Boado, R. J. Delivery of pharmaceutical agents via the human insulin receptor. United States Patent 7,388,079, 2008.
25. Regina, A.; Demeule, M.; Che, C.; Lavallee, I.; Poirier, J.; Gabathuler, R.; Beliveau, R.; Castaigne, J. P. Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br. J. Pharmacol. 2008, 155 (2), 185-197.
26. Bihorel, S.; Camenisch, G.; Lemaire, M.; Scherrmann, J. M. Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar. Pharm. Res. 2007, 24 (9), 1720-1728.
27. Jolliet-Riant, P.; Tillement, J. P. Drug transfer across the bloodbrain barrier and improvement of brain delivery. Fundam. Clin. Pharmacol. 1999, 13 (1), 16-26.
28. Marchi, N.; Angelov, L.; Masaryk, T.; Fazio, V.; Granata, T.; Hernandez, N.; Hallene, K.; Diglaw, T.; Franic, L.; Najm, I.; Janigro, D. Seizure-promoting effect of blood-brain barrier disruption. Epilepsia 2007, 48 (4), 732-742. (Pubitemid 46587627)
29. Lord, J. A. H.; Waterfield, A. A.; Hughes, J.; Kosterlitz, H. W. Endogenous opioid peptides - multiple agonists and receptors. Nature 1977, 267 (5611), 495-499. (Pubitemid 8098466)
30. Chan, W. C.; White, P. D. Chapter 3. Basic Procedures. In Fmoc Solid Phase Peptide Synthesis: a practical approach, 1st ed.; Chan, W. C., White, P. D., Eds.; Oxford University Press: Oxford, 2000; p 61.
31. Siew, A.; Le, H.; Thiovolet, M.; Gellert, P.; Schatzlein, A.; Uchegbu, I. Enhanced Oral Absorption of Hydrophobic and Hydrophilic Drugs Using Quaternary Ammonium Palmitoyl Glycol Chitosan Nanoparticles. Mol. Pharmaceutics 2012, 9 (1), 14-28.
32. Mohamadi, F.; Richards, N.; Guida, W.; Liskamp, R.; Lipton, M.; Caulfield, C.; Chang, G.; Hendrickson, T.; Still, W. Macro- Model - an integrated software system for modeling organic and bioorganic molecules using molecular mechanics. J. Comput. Chem. 1990, 11, 440-67.
33. Chang, G.; Guida, W. C.; Still, W. C. An internal coordinate monte-carlo method for searching conformational space. J. Am. Chem. Soc. 1989, 111 (12), 4379-4386.
34. Still, W. C.; Tempczyk, A.; Hawley, R. C.; Hendrickson, T. Semianalytical treatment of solvation for molecular mechanics and dynamics. J. Am. Chem. Soc. 1990, 112 (16), 6127-6129.
35. Jorgensen, W. L.; Maxwell, D. S.; TiradoRives, J. Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J. Am. Chem. Soc. 1996, 118 (45), 11225-11236.
36. Liederer, B. M.; Borchardt, R. T. Stability of oxymethyl-modified coumarinic acid cyclic prodrugs of diastereomeric opioid peptides in biological media from various animal species including human. J. Pharm. Sci. 2005, 94 (10), 2198-2206. (Pubitemid 41665281)
37. British Pharmacopoeial Commission, British Pharmacopoeia, Appendix 1A; TSO: Norwich, U.K., 2007; Vol. IV, p A61.
38. Cheng, W.; Satyanarayanajois, S.; Lim, L. Y. Aqueous-soluble, non-reversible lipid conjugate of salmon calcitonin: synthesis, characterization and in vivo activity. Pharm. Res. 2007, 24 (1), 99-110.
39. Richardson, S. C. W.; Kolbe, H. J. V.; Duncan, R. Potential of low molecular mass chitosan as a DNA delivery system: biocompatibility, body distribution and ability to complex and protect DNA. Int. J. Pharm. 1999, 178 (2), 231-243. (Pubitemid 29078577)
40. Polt, R.; Porreca, F.; Szabo, L. Z.; Bilsky, E. J.; Davis, P.; Abbruscato, T. J.; Davis, T. P.; Horvath, R.; Yamamura, H. I.; Hruby, V. J. Glycopeptide enkephalin analogs produce analgesia in mice -evidence for penetration of the blood-brain-barrier. Proc. Natl. Acad. Sci. U.S.A. 1994, 91 (15), 7114-7118. (Pubitemid 24226813)
41. Cheng, W. P.; Gray, A. I.; Tetley, L.; Hang, T. L. B.; Schatzlein, A. G.; Uchegbu, I. F. Polyelectrolyte nanoparticles with high drug loading enhance the oral uptake of hydrophobic compounds. Biomacromolecules 2006, 7 (5), 1509-1520. (Pubitemid 43811207)
42. Uchegbu, I. F.; Lane, M.; Schatzlein, A. G., Nanomedicines from polymeric amphiphiles. In Handbook of Materials for Nanomedicine; Torchilin, V. P., Amiji, M., Eds.; Pan Stanford Publishing: Singapore, 2010; pp 495-513.
43. Blomberg, D.; Kreye, P.; Fowler, C.; Brickmann, K.; Kihlberg, J. Synthesis and biological evaluation of leucine enkephalin turn mimetics. Org. Biomol. Chem. 2006, 4 (3), 416-423.
44. Kane, B. E.; Svensson, B.; Ferguson, D. M. Molecular recognition of opioid receptor ligands. AAPS J. 2006, 8 (1), E126-E137.
45. vanderSpoel, D.; Berendsen, H. J. C. Molecular dynamics simulations of leu-enkephalin in water and DMSO. Biophys. J. 1997, 72 (5), 2032-2041.
46. Aburi, M.; Smith, P. E. A conformational analysis of leucine enkephalin as a function of pH. Biopolymers 2002, 64 (4), 177-188. (Pubitemid 34712550)
47. Jun, H. W.; Paramonov, S. E.; Hartgerink, J. D. Biomimetic selfassembled nanofibers. Soft Matter 2006, 2 (3), 177-181.
48. Qu, X. Z.; Khutoryanskiy, V. V.; Stewart, A.; Rahman, S.; Papahadjopoulos-Sternberg, B.; Dufes, C.; McCarthy, D.; Wilson, C. G.; Lyons, R.; Carter, K. C.; Schatzlein, A.; Uchegbu, I. F. Carbohydrate-based micelle clusters which enhance hydrophobic drug bioavailability by up to 1 order of magnitude. Biomacromolecules 2006, 7 (12), 3452-3459. (Pubitemid 46111801)
49. Fredholt, K.; Adrian, C.; Just, L.; Hoj Larsen, D.; Weng, S.; Moss, B.; Juel Friis, G. Chemical and enzymatic stability as well as transport properties of a Leu-enkephalin analogue and ester prodrugs thereof. J. Controlled Release 2000, 63 (3), 261-273.
50. Garreau, I.; Pejoan, C.; Bressollier, P.; Verneuil, B.; Cucumel, K.; Cupo, A. Purification and characterization of enkephalin-related peptides released by in-vitro peptic digestion of bovine plasmaproteins. Peptides 1994, 15 (7), 1195-1204.
51. Zoellner, C.; Mousa, S. A.; Fischer, O.; Rittner, H. L.; Shaqura, M.; Brack, A.; Shakibaei, M.; Binder, W.; Urban, F.; Stein, C.; Schaefer, M. Chronic morphine use does not induce peripheral tolerance in a rat model of inflammatory pain. J. Clin. Invest. 2008, 118 (3), 1065-1073.
52. Gregoriadis, G.; Ryman, B. Fate of protein containing liposomes injected into rats. Eur. J. Biochem. 1972, 24, 484-491.
53. Stoiber, W.; Sanger, A. M.; Lembeck, F. Different modes of action of morphine and epibatidine in Straub tail reactions in mice. Arzneim. Forsch. 2000, 50 (8), 683-7. (Pubitemid 30642802)
54. Srimal, R. C.; Jaitly, K. D.; Bhargava, K. P. Effect of muscle relaxants on the straub tail phenomenon. Jpn. J. Pharmacol. 1965, 15, 323.
55. Woodley, J. F. Enzymatic Barriers for Gi Peptide and Protein Delivery. Crit. Rev. Ther. Drug Carrier Syst. 1994, 11 (2-3), 61-95.
56. Franklin, K. B. J.; Abbott, F. V., Techniques for Assessing the Effects of Drugs on Nociceptive Responses. In Neuromethods 13: Psychopharmacology; Boulton, A. A., Baker, G. B., Greensham, A. J., Eds.; Humana Press Inc.: Clifton, NJ, 1989; pp 145-216.
57. Field, S.; Newton-Bishop, J. A. Melanoma and vitamin D. Mol. Oncol. 2011, 5 (2), 197-214.
58. Jinsmaa, Y.; Miyazaki, A.; Fujita, Y.; Li, T. Y.; Fujisawa, Y.; Shiotani, K.; Tsuda, Y.; Yokoi, T.; Ambo, A.; Sasaki, Y.; Bryant, S. D.; Lazarus, L. H.; Okada, Y. Oral bioavailability of a new class of muopioid receptor agonists containing 3,6-bis[Dmt-NH(CH2)(n)]2- (1H)-pyrazinone with central-mediated analgesia. J. Med. Chem. 2004, 47 (10), 2599-2610. (Pubitemid 38580096)
59. Stadelmann, W. K.; Reintgen, D. S. Diagnosis in malignant melanoma. Hematol. Oncol. Clin. North Am. 1998, 12 (4), 767.
60. Young, S. E.; Martinez, S. R.; Essner, R. The role of surgery in treatment of stage IV melanoma. J. Surg. Oncol. 2006, 94 (4), 344-351. (Pubitemid 44330859)
61. Ott, P. A.; Hamilton, A.; Min, C.; Safarzadeh-Amiri, S.; Goldberg, L.; Yoon, J.; Yee, H.; Buckley, M.; Christos, P. J.; Wright, J. J.; Polsky, D.; Osman, I.; Liebes, L.; Pavlick, A. C. A Phase II Trial of Sorafenib in Metastatic Melanoma with Tissue Correlates. PLoS One 2010, 5 (12), e15588.
62. Das, D.; Lin, S. S. Double-coated poly (butylcynanoacrylate) nanoparticulate delivery systems for brain targeting of dalargin via oral administration. J. Pharm. Sci. 2005, 94 (6), 1343-1353.
63. Schroeder, U.; Sommerfeld, P.; Sabel, B. A. Efficacy of oral dalargin-loaded nanoparticle delivery across the blood-brain barrier. Peptides 1998, 19 (4), 777-780. (Pubitemid 28255016)
64. Olivier, J. C.; Fenart, L.; Chauvet, R.; Pariat, C.; Cecchelli, R.; Couet, W. Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity. Pharm. Res. 1999, 16 (12), 1836-1842. (Pubitemid 30040699)